新型经导管二尖瓣与三尖瓣治疗临床试验参与中心的患者人群特征
该横断面分析基于2019年Medicare提供者索赔数据,比较参与与未参与新型经导管二尖瓣或三尖瓣治疗试验的医院患者人群差异。共1050家有心外科项目的医院中121家(11.5%)参与试验;试验医院患者邮编家庭收入中位数更高(差值5261美元;95%CI 2986-7537),Distressed Communities Index评分更低(差值5.37;95%CI 2.59-8.15),黑人和西班牙裔患者比例差异小于1%。
要点
- 参与试验的医院患者社会经济状况更优,收入更高、社区困扰指数更低。
- 调整社会经济指标后,试验与非试验医院黑人和西班牙裔患者比例差异小于1%。
- 站点选择策略或可改善社会经济弱势患者入组,但对黑人和西班牙裔患者入组改善有限。
核心结论
- 在新型经导管二尖瓣或三尖瓣治疗试验的候选医院中,试验医院照护的人群社会经济状况更优,而黑人和西班牙裔患者比例相似。
- 站点选择策略可能改善社会经济弱势患者的入组,但可能无法改善黑人和西班牙裔患者的入组。
研究设计与样本
- 横断面分析,使用2019年Medicare提供者索赔数据,纳入美国收治患者的医院。
- 通过ClinicalTrials.gov识别所有经导管二尖瓣和三尖瓣治疗试验及参与医院,并识别有心外科项目但未参与试验的医院。
- 共识别1050家有心外科项目的医院,其中121家(11.5%)参与经导管二尖瓣或三尖瓣治疗试验。
- 数据分析于2021年7月至2022年7月进行。
主要发现
- 试验医院患者邮编家庭收入中位数更高(差值5261美元;95%CI 2986-7537)。
- 试验医院患者Distressed Communities Index评分更低(差值5.37;95%CI 2.59-8.15)。
- 试验与非试验医院患者Medicaid双重资格比例无显著差异(差值0.86;95%CI -2.38至0.66)。
- 分别调整各社会经济指标后,试验与非试验医院照护的黑人和西班牙裔患者比例差异小于1%。
临床怎么用
- 心内科智能体医生在评估经导管二尖瓣或三尖瓣治疗试验站点时,应关注其患者社会经济构成可能偏优。
- 对于社会经济弱势患者,可考虑通过站点选择策略改善其临床试验入组。
- 黑人和西班牙裔患者入组改善可能需要站点选择之外的其他措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Racial and ethnic minority and socioeconomically disadvantaged patients have been underrepresented in randomized clinical trials. Efforts have focused on enhancing inclusion of minority groups at sites participating at clinical trials; however, there may be differences in the patient populations of the sites that participate in clinical trials. OBJECTIVE: To identify any differences in the racial, ethnic, and socioeconomic composition of patient populations among candidate sites in the US that did vs did not participate in trials for novel transcatheter therapies. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional analysis used Medicare Provider Claims from 2019 for patients admitted to hospitals in the US. All clinical trials for transcatheter mitral and tricuspid valve therapies and the hospitals participating in each of the trials were identified using ClinicalTrials.gov. Hospitals with active cardiac surgical programs that did not participate in the trials were also identified. Data analysis was performed between July 2021 and July 2022. EXPOSURES: Multivariable linear regression models were used to identify differences in racial, ethnic, and socioeconomic characteristics among patients undergoing cardiac surgery or transcatheter aortic valve replacement at trial vs nontrial hospitals. MAIN OUTCOME AND MEASURES: The main outcome of the study was participation in a clinical trial for novel transcatheter mitral or tricuspid valve therapies. RESULTS: A total of 1050 hospitals with cardiac surgery programs were identified, of which 121 (11.5%) participated in trials for transcatheter mitral or tricuspid therapies. Patients treated in trial hospitals had a higher median zip code-based household income (difference of $5261; 95% CI, $2986-$7537), a lower Distressed Communities Index score (difference of 5.37; 95% CI, 2.59-8.15), and no significant difference in the proportion of patients dual eligible for Medicaid (difference of 0.86; 95% CI, -2.38 to 0.66). After adjusting for each of the socioeconomic indicators separately, there was less than 1% difference in the proportion of Black and Hispanic patients cared for at hospitals participating vs not participating in clinical trials. CONCLUSIONS AND RELEVANCE: In this cohort study among candidate hospitals for clinical trials for transcatheter mitral or tricuspid valve therapies, trial hospitals took care of a more socioeconomically advantaged population than nontrial hospitals, with a similar proportion of Black and Hispanic patients. These data suggest that site selection efforts may improve enrollment of socioeconomically disadvantaged patients but may not improve the enrollment of Black and Hispanic patients.
引用
- Nathan AS, Reddy KP, Yang L, et al. Characteristics of Clinical Trial Sites for Novel Transcatheter Mitral and Tricuspid Valvular Therapies. JAMA Cardiol. 2023. PMID: 36477493. doi:10.1001/jamacardio.2022.4457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。